Difference between revisions of "Naftidrofuryl"

Jump to: navigation, search
m
Line 24: Line 24:
 
| routes_of_administration =  
 
| routes_of_administration =  
 
}}
 
}}
 +
__NOTOC__
 +
{{SI}}
 +
{{CMG}}
  
{{CMG}}{{AE}}{{SS}}
+
==Overview==
  
'''Naftidrofuryl''' ([[International Nonproprietary Name|INN]], also known as '''nafronyl''' or as the [[oxalate]] salt '''nafronyl oxalate''') is a drug used in the management of peripheral and [[cerebral]] [[Blood vessel|vascular]] disorders. It is claimed to enhance cellular oxidative capacity and to be a [[spasmolytic]].<ref>{{cite book |author=Reynolds, J.E.F. (ed.)|title=[[Martindale: The complete drug reference|Martindale: The extra pharmacopoeia]] |publisher=Pharmaceutical Press |location=London |year=1993 |edition=30th edition |pages=p. 1310 |isbn=0853693005}}</ref> It may also be a  [[5-HT receptor|5-HT<sub>2</sub> receptor]] [[receptor antagonist|antagonist]].
+
'''Naftidrofuryl''' ([[International Nonproprietary Name|INN]], also known as '''nafronyl''' or as the [[oxalate]] salt '''naftidrofuryl oxalate''' or '''nafronyl oxalate''') is a drug used in the management of peripheral and [[Cerebrum|cerebral]] [[Blood vessel|vascular]] disorders. It is claimed to enhance cellular oxidative capacity and to be a [[muscle relaxant#Spasmolytics|spasmolytic]].<ref>{{cite book |author=Reynolds, J.E.F. (ed.)|title=[[Martindale: The complete drug reference|Martindale: The extra pharmacopoeia]] |publisher=Pharmaceutical Press |location=London |year=1993 |edition=30th edition |isbn=0-85369-300-5 |page=1310}}</ref> It may also be a  [[5-HT receptor|5-HT<sub>2</sub> receptor]] [[receptor antagonist|antagonist]]. It is also licenced for the treatment of [[intermittent claudication]] due to peripheral arterial disease.
 +
 
 +
It is sold under the brand name [[Dusodril]] ([[Merck & Co.|Merck]]) and cerebromap for multiapex in middle east. It is also sold as Praxilene in the United Kingdom.<ref>http://www.patient.co.uk/medicine/naftidrofuryl</ref>
 +
 
 +
Historically, it has been used to treat sudden [[idiopathic]] hearing loss and acute [[tinnitus]].<ref>http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm</ref>
 +
 
 +
Naftidrofuryl may be effective for relieving the pain of muscle [[cramp]]s.<ref name=Katzberg>{{cite journal |author=Katzberg HD, Khan AH, So YT |title=Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology |journal=Neurology |volume=74 |issue=8 |pages=691–6 |date=February 2010 |pmid=20177124 |doi=10.1212/WNL.0b013e3181d0ccca |url=}}</ref>
  
 
==References==
 
==References==
{{Reflist|2}}
+
{{reflist|2}}
 +
 
 +
{{Peripheral vasodilators}}
  
 
[[Category:Vasodilators]]
 
[[Category:Vasodilators]]
[[Category:Naphthalenes]]
+
[[Category:Cardiovascular Drugs]]
[[Category:Tetrahydrofurans]]
+
[[Category:Drug]]
[[Category:Carboxylate esters]]
 
[[Category:Amines]]
 
[[Category:Cardiovascular Drugs]][[Category:Drugs]]
 
 
 
{{pharma-stub}}
 
{{Peripheral vasodilators}}
 
{{WikiDoc Sources}}
 

Revision as of 04:55, 25 July 2014

Naftidrofuryl
File:Naftidrofuryl.svg
Clinical data
ATC code
Identifiers
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC24H33NO3
Molar mass383.524 g/mol

WikiDoc Resources for Naftidrofuryl

Articles

Most recent articles on Naftidrofuryl

Most cited articles on Naftidrofuryl

Review articles on Naftidrofuryl

Articles on Naftidrofuryl in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Naftidrofuryl

Images of Naftidrofuryl

Photos of Naftidrofuryl

Podcasts & MP3s on Naftidrofuryl

Videos on Naftidrofuryl

Evidence Based Medicine

Cochrane Collaboration on Naftidrofuryl

Bandolier on Naftidrofuryl

TRIP on Naftidrofuryl

Clinical Trials

Ongoing Trials on Naftidrofuryl at Clinical Trials.gov

Trial results on Naftidrofuryl

Clinical Trials on Naftidrofuryl at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Naftidrofuryl

NICE Guidance on Naftidrofuryl

NHS PRODIGY Guidance

FDA on Naftidrofuryl

CDC on Naftidrofuryl

Books

Books on Naftidrofuryl

News

Naftidrofuryl in the news

Be alerted to news on Naftidrofuryl

News trends on Naftidrofuryl

Commentary

Blogs on Naftidrofuryl

Definitions

Definitions of Naftidrofuryl

Patient Resources / Community

Patient resources on Naftidrofuryl

Discussion groups on Naftidrofuryl

Patient Handouts on Naftidrofuryl

Directions to Hospitals Treating Naftidrofuryl

Risk calculators and risk factors for Naftidrofuryl

Healthcare Provider Resources

Symptoms of Naftidrofuryl

Causes & Risk Factors for Naftidrofuryl

Diagnostic studies for Naftidrofuryl

Treatment of Naftidrofuryl

Continuing Medical Education (CME)

CME Programs on Naftidrofuryl

International

Naftidrofuryl en Espanol

Naftidrofuryl en Francais

Business

Naftidrofuryl in the Marketplace

Patents on Naftidrofuryl

Experimental / Informatics

List of terms related to Naftidrofuryl

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Naftidrofuryl (INN, also known as nafronyl or as the oxalate salt naftidrofuryl oxalate or nafronyl oxalate) is a drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic.[1] It may also be a 5-HT2 receptor antagonist. It is also licenced for the treatment of intermittent claudication due to peripheral arterial disease.

It is sold under the brand name Dusodril (Merck) and cerebromap for multiapex in middle east. It is also sold as Praxilene in the United Kingdom.[2]

Historically, it has been used to treat sudden idiopathic hearing loss and acute tinnitus.[3]

Naftidrofuryl may be effective for relieving the pain of muscle cramps.[4]

References

  1. Reynolds, J.E.F. (ed.) (1993). Martindale: The extra pharmacopoeia (30th edition ed.). London: Pharmaceutical Press. p. 1310. ISBN 0-85369-300-5.
  2. http://www.patient.co.uk/medicine/naftidrofuryl
  3. http://www.der-arzneimittelbrief.de/Jahrgang2004/Ausgabe12Seite89.htm
  4. Katzberg HD, Khan AH, So YT (February 2010). "Assessment: Symptomatic treatment for muscle cramps (an evidence-based review): Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology". Neurology. 74 (8): 691–6. doi:10.1212/WNL.0b013e3181d0ccca. PMID 20177124.

Linked-in.jpg